Beta Drugs enterprise value

·UnclassifiedChart ›
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
1,875——
0.51250.2
37.00.00.0
148148—
2,059——
14723.0—
₹2,031.59——
623393—
23.7%37.7%—
0.07×——
4.64×——
22.31×——
27.77×——
Reference items — trailing FY values
444385362
92.375.774.6
74.258.562.1
—37.331.6
−16.2−16.2−5.3
—−19.8−7.0
—53.536.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,849.70

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,875 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——1,875.0
- Cash, Equiv & ST Investments0.2124.80.5
+ Minority Interest0.00.037.0
+ Total Debt—147.8147.8
Enterprise Value——2,059.4
Net Debt (memo)—23.0147.4
EV per Share——2,031.59
Total Capital—392.6622.5
Total Debt/Total Capital—37.6523.74
Total Debt/EV——0.07
EV/Sales——4.64
EV/EBITDA——22.31
EV/EBIT——27.77
Reference Items — Trailing FY Values
Sales362.4384.8444.3
EBITDA74.675.792.3
EBIT62.158.574.2
Operating Cash Flow31.637.3—
Free Cash Flow-5.3-16.2-16.2
FCFF (free cash flow to the firm)-7.0-19.8—
Capital Expenditure36.953.5—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.